New drug duo takes on rare liver virus in head-to-head trial
NCT ID NCT07142811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two experimental drugs (Tobevibart and Elebsiran) works better than the current treatment Bulevirtide for people with chronic hepatitis D, a serious liver infection. About 100 adults with stable liver disease will receive either the combo or the standard drug. The main goal is to see if the combo can make the virus undetectable in the blood and keep it that way for 24 weeks after treatment ends.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative
Valencia, 46014, Spain
-
Investigative Site
Brussels, 1020, Belgium
-
Investigative Site
Brussels, 1070, Belgium
-
Investigative Site
Edegem, 2650, Belgium
-
Investigative Site
Sofia, 1407, Bulgaria
-
Investigative Site
Sofia, 1431, Bulgaria
-
Investigative Site
Stara Zagora, 6003, Bulgaria
-
Investigative Site
Clichy, 92110, France
-
Investigative Site
Créteil, 94000, France
-
Investigative Site
Limoges, 87042, France
-
Investigative Site
Rennes, 35000, France
-
Investigative Site
Toulouse, 31059, France
-
Investigative Site
Hanover, 30625, Germany
-
Investigative Site
Chisinau, 2025, Moldova
-
Investigative Site
Amsterdam, 1081 HV, Netherlands
-
Investigative Site
Nijmegen, 6525 GA, Netherlands
-
Investigative Site
Rotterdam, 3015 GD, Netherlands
-
Investigative Site
Karachi, 74800, Pakistan
-
Investigative Site
Karachi, 75600, Pakistan
-
Investigative Site
Lahore, 54800, Pakistan
-
Investigative Site
Rawalpindi, 46000, Pakistan
-
Investigative Site
Bucharest, 021105, Romania
-
Investigative Site
Bucharest, 022328, Romania
-
Investigative Site
Bucharest, 030303, Romania
-
Investigative Site
Barcelona, 08028, Spain
-
Investigative Site
Madrid, 28064, Spain
-
Investigative Site
Kyiv, 01135, Ukraine
-
Investigative Site
London, E1 1BB, United Kingdom
-
Investigative Site
London, SE5 9RS, United Kingdom
-
Investigative Site
Manchester, M8 5RB, United Kingdom
-
Investigative Site
Nottingham, NG7 2UH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hepatitis b drug showdown: which is safer for kidneys?
- New ultrasound technique aims to better measure liver health
- New Free-Breathing MRI could make liver scans easier for kids
- New MRI scan could replace liver biopsies
- New drug duo aims to control hard-to-treat hepatitis delta
- New drug combo aims to tackle stubborn hepatitis d